research use only

Betamethasone Glucocorticoid Receptor agonist

Name: Betamethasone
Brand: Selleck Chemicals
SKU: S1500
Availability: InStock
Rating: 5 (2 reviews)

Cat.No.S1500

Betamethasone (NSC-39470, SCH-4831) is a glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.

Chemical Structure

Molecular Weight: 392.46

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability

Quality Control

Batch: Purity: 99.96%

99.96

Related Targets	Adrenergic Receptor Estrogen/progestogen Receptor GPR Androgen Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES Aromatase CCK receptor 5-alpha Reductase Mineralocorticoid Receptor GHSR SSTR TSH Receptor GNRH Receptor PGDS
Related Products	AL082D06 (20S)-Protopanaxatriol Corticosterone Glucocorticoid Receptor Antibody [D9N22] Cortodoxone

Chemical Information, Storage & Stability

Molecular Weight	392.46	Formula	C₂₂H₂₉FO₅	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	378-44-9	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	NSC-39470, SCH-4831			Smiles	CC1CC2C3CCC4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)CO)O)C)O)F)C

Solubility

In vitro
Batch:

DMSO : 79 mg/mL (201.29 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 10 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	Glucocorticoid receptor ^[1]
In vitro	Betamethasone has a specific affinity for type II glucocorticoid receptors which are present in most brain regions. ^[1]
In vivo	Betamethasone has direct vasoconstrictor effects on peripheral femoral resistance vessels in late gestation fetal sheep. This compound exposure decreases cerebral blood flow (CBF) in all brain regions measured except the hippocampus after 24 hours of infusion in sheep. ^[1] It reduces the activation of NF-kappaB and elevation of TNFalpha and IL-1beta, and induces the expression of IL-10 in the brain, all of which correlate with the changes of pain thresholds in rats. ^[2] This chemical exposure reduces synaptophysin-LI in the frontal neocortex, caudate putamen and hippocampus by 46.9%, 41.0% and 55.4%, respectively, that is not accompanied by irreversible neuronal damage in the fetal sheep brain. ^[3] It modestly increases cytidylyltransferase (CT) mRNA, but does not alter the levels of immunoreactive enzyme in adult rat lung. This compound decreases the activities of the sphingomyelin hydrolases: acid sphingomyelinase by 33% and of alkaline ceramidase by 21%. ^[4] It injected at the time of nerve injury partially inhibits the development of neuropathic hyperalgesia and reduces the subsequent elevated levels of pro-inflammatory cytokines in the brain of rats, while stimulating the expression of the anti-inflammatory cytokine IL-10. ^[5]
References	[1] https://pubmed.ncbi.nlm.nih.gov/11060135/ [2] https://pubmed.ncbi.nlm.nih.gov/16501235/ [3] https://pubmed.ncbi.nlm.nih.gov/11137749/ [4] https://pubmed.ncbi.nlm.nih.gov/8761490/ [5] https://pubmed.ncbi.nlm.nih.gov/16253423/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04770805	Recruiting	Sacral Myelomeningocele\|Neural Tube Defects\|Spina Bifida	Assistance Publique - Hôpitaux de Paris	April 16 2021	Not Applicable
NCT03210545	Unknown status	Addison Disease	Göteborg University	March 2 2021	Phase 4
NCT06264973	Recruiting	Preterm Birth	Erasmus Medical Center	January 1 2021	--

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):